Clinical trial
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients…
NCT00210470 · Brooklyn ImmunoTherapeutics, LLC, Industry · Completed
Key facts
| NCT number | NCT00210470 |
|---|---|
| Title | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer |
| Official title | A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck |
| Lead sponsor | Brooklyn ImmunoTherapeutics, LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Squamous Cell Carcinoma of the Head and Neck |
| Intervention type | Biological, Drug |
| Interventions | IRX-2, Cyclophosphamide, Indomethacin, Zinc, Omeprazole |
| Enrollment | 27 |
| Start date | Jul 1, 2005 |
| Primary completion | Dec 1, 2010 |
| Completion | Mar 1, 2012 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 11, 2020 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: